These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1111 related articles for article (PubMed ID: 24484236)

  • 21. Personalized peptide vaccination in patients with refractory non-small cell lung cancer.
    Yoshiyama K; Terazaki Y; Matsueda S; Shichijo S; Noguchi M; Yamada A; Mine T; Ioji T; Itoh K; Shirouzu K; Sasada T; Takamori S
    Int J Oncol; 2012 May; 40(5):1492-500. PubMed ID: 22307435
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive clinical outcome of the intratumoral CD66b-positive neutrophil-to-CD8-positive T-cell ratio in patients with resectable nonsmall cell lung cancer.
    Ilie M; Hofman V; Ortholan C; Bonnetaud C; Coëlle C; Mouroux J; Hofman P
    Cancer; 2012 Mar; 118(6):1726-37. PubMed ID: 21953630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of dendritic cell vaccines pulsed with Wilms' tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers.
    Takahashi H; Okamoto M; Shimodaira S; Tsujitani S; Nagaya M; Ishidao T; Kishimoto J; Yonemitsu Y;
    Eur J Cancer; 2013 Mar; 49(4):852-9. PubMed ID: 23245331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Myeloid and lymphoid dendritic cells and cytotoxic T lymphocytes in peripheral blood of non-small cell lung cancer patient--a pilot study.
    Krawczyk P; Wojas K; Milanowski P; Roliński J
    Adv Med Sci; 2006; 51():160-3. PubMed ID: 17357299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tertiary lymphoid structures target the antitumor immune response to lung cancer.
    Randall TD; Kern JA
    Am J Respir Crit Care Med; 2014 Apr; 189(7):767-9. PubMed ID: 24684357
    [No Abstract]   [Full Text] [Related]  

  • 26. Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer.
    Chen JJ; Yao PL; Yuan A; Hong TM; Shun CT; Kuo ML; Lee YC; Yang PC
    Clin Cancer Res; 2003 Feb; 9(2):729-37. PubMed ID: 12576442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer.
    Di Modugno F; Di Carlo A; Spada S; Palermo B; D'Ambrosio L; D'Andrea D; Morello G; Belmonte B; Sperduti I; Balzano V; Gallo E; Melchionna R; Panetta M; Campo G; De Nicola F; Goeman F; Antoniani B; Carpano S; Frigè G; Warren S; Gallina F; Lambrechts D; Xiong J; Vincent BG; Wheeler N; Bortone DS; Cappuzzo F; Facciolo F; Tripodo C; Visca P; Nisticò P
    EBioMedicine; 2024 Mar; 101():105003. PubMed ID: 38340557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single-cell transcriptome and antigen-immunoglobin analysis reveals the diversity of B cells in non-small cell lung cancer.
    Chen J; Tan Y; Sun F; Hou L; Zhang C; Ge T; Yu H; Wu C; Zhu Y; Duan L; Wu L; Song N; Zhang L; Zhang W; Wang D; Chen C; Wu C; Jiang G; Zhang P
    Genome Biol; 2020 Jun; 21(1):152. PubMed ID: 32580738
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immature central tumor tertiary lymphoid structures are associated with better prognosis in non-small cell lung cancer.
    Xiaoxu D; Min X; Chengcheng C
    BMC Pulm Med; 2024 Mar; 24(1):155. PubMed ID: 38532454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical significance of expression of cancer/testis antigen and down-regulation of HLA class-I in patients with stage I non-small cell lung cancer.
    Hanagiri T; Shigematsu Y; Shinohara S; Takenaka M; Oka S; Chikaishi Y; Nagata Y; Baba T; Uramoto H; So T; Yamada S
    Anticancer Res; 2013 May; 33(5):2123-8. PubMed ID: 23645764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD4/CD8 co-expression shows independent prognostic impact in resected non-small cell lung cancer patients treated with adjuvant radiotherapy.
    Hald SM; Bremnes RM; Al-Shibli K; Al-Saad S; Andersen S; Stenvold H; Busund LT; Donnem T
    Lung Cancer; 2013 May; 80(2):209-15. PubMed ID: 23384671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor-related leucocytosis and chemotherapy-induced neutropenia: linked or independent prognostic factors for advanced non-small cell lung cancer?
    Maione P; Rossi A; Di Maio M; Gridelli C
    Lung Cancer; 2009 Oct; 66(1):8-14. PubMed ID: 19328587
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A dendritic cell-based tumour vaccine for lung cancer: full-length XAGE-1b protein-pulsed dendritic cells induce specific cytotoxic T lymphocytes in vitro.
    Zhou Q; Guo AL; Xu CR; An SJ; Wang Z; Yang SQ; Wu YL
    Clin Exp Immunol; 2008 Sep; 153(3):392-400. PubMed ID: 18803763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intratumoral tertiary lymphoid structure (TLS) maturation is influenced by draining lymph nodes of lung cancer.
    He M; He Q; Cai X; Liu J; Deng H; Li F; Zhong R; Lu Y; Peng H; Wu X; Chen Z; Lao S; Li C; Li J; He J; Liang W
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37072348
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of monocyte-derived dendritic cells from colorectal cancer patients, non-small-cell-lung-cancer patients and healthy donors.
    Kvistborg P; Bechmann CM; Pedersen AW; Toh HC; Claesson MH; Zocca MB
    Vaccine; 2009 Dec; 28(2):542-7. PubMed ID: 19837091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stromal CD4/CD25 positive T-cells are a strong and independent prognostic factor in non-small cell lung cancer patients, especially with adenocarcinomas.
    Kayser G; Schulte-Uentrop L; Sienel W; Werner M; Fisch P; Passlick B; Zur Hausen A; Stremmel C
    Lung Cancer; 2012 Jun; 76(3):445-51. PubMed ID: 22300751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Calreticulin Expression in Human Non-Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis.
    Fucikova J; Becht E; Iribarren K; Goc J; Remark R; Damotte D; Alifano M; Devi P; Biton J; Germain C; Lupo A; Fridman WH; Dieu-Nosjean MC; Kroemer G; Sautès-Fridman C; Cremer I
    Cancer Res; 2016 Apr; 76(7):1746-56. PubMed ID: 26842877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blood group antigen A and flow cytometric analysis in resected early-stage non-small cell lung cancer.
    Graziano SL; Tatum AH; Gonchoroff NJ; Newman NB; Kohman LJ
    Clin Cancer Res; 1997 Jan; 3(1):87-93. PubMed ID: 9815542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.
    Izar B; Sequist L; Lee M; Muzikansky A; Heist R; Iafrate J; Dias-Santagata D; Mathisen D; Lanuti M
    Ann Thorac Surg; 2013 Sep; 96(3):962-8. PubMed ID: 23932319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance.
    Yoshida N; Abe H; Ohkuri T; Wakita D; Sato M; Noguchi D; Miyamoto M; Morikawa T; Kondo S; Ikeda H; Nishimura T
    Int J Oncol; 2006 May; 28(5):1089-98. PubMed ID: 16596224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.